Zacks Investment Research on MSN2d
Amgen Rises Almost 22% YTD: Should You Buy, Hold or Sell the Stock?
Amgen’s AMGN stock has risen 21.7% so far this year compared with an increase of 7% for the industry. AMGN Stock Performance ...
UnitedHealth eases rules on renewing some prescription drugs
UnitedHealth Group's pharmacy benefit manager, Optum Rx, said on Wednesday it would ease requirements to get insurance ...
Prediction: These 2 Stocks Will Outperform the Market Through 2030
The more we extend our horizon, the more likely it is that stocks will provide juicy returns. Investors can cash in by ...
Amgen's Options: A Look at What the Big Money is Thinking
The general mood among these heavyweight investors is divided, with 70% leaning bullish and 20% bearish. Among these notable ...
Fierce Pharma7d
Argenx's Vyvgart tops Trinity’s latest launch success analysis, beating out several Big Pharma debuts
Treatments for autoimmune diseases and those in orphan markets are on the up and up, as are drugmakers’ first launches, ...
Nasdaq7d
Amgen's Options: A Look at What the Big Money is Thinking
Amgen 30-Day Option Volume & Interest Snapshot Amgen is a leader in biotechnology-based human therapeutics. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system ...